AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05290753 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prokinetic Motility Agents as primpiram and gastreg
Description: Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis
Study NCT06395051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester
Description: Ketone monoester supplement (395 mg/kg body mass)
Study NCT06395051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be taste-matched to the active supplement for bitterness using denatonium benzoate and volume-matched with water
Study NCT06144021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey postbiotics derived from kefir lactic acid bacteria
Description: Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
Study NCT06144021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
Study NCT05155215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Description: IM19 CAR-T cells will be administered at dose level: 100×10\^6 CAR-T cells or 200×10\^6 CAR-T cells
Study NCT05155215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 per day for 3 days (IV)
Study NCT05155215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 per day for 3 days (IV)
Study NCT05305170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of EETs, DHETs and HETEs
Description: The plasmatic concentration of EETs, DHETs, and HETEs.
Study NCT05057221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Uproleselan 20 mg/kg BID up to maximum dose of 2500 mg, infused IV over 20 minutes on days 1-7 or until hospital discharge. It should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.
Study NCT04893551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tilvestamab
Description: Tilvestamab will be administered as IV infusion.
Study NCT05469529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 5mcg dexmedetomidine to be given intrathecally along with 0.5% bupivacaine.
Study NCT05535608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SRW Cel System
Description: Dietary supplement
Study NCT05855837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Eat Cereal
Description: Cereal products available in retail stores
Study NCT06195618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide pulsed autologous Dendritic cell
Description: Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
Study NCT05499884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasound
Description: Endovaginal ultrasound will be performed in the operating room by the radiology team to:~1. to confirm the operative indication for a rectal shaving ;~2. to confirm the complete removal of the lesion
Study NCT04659707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xe129
Description: Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Study NCT04527029 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: It is an observational study. No interventions.
Study NCT05724342 — intervention group
Intervention type: DRUG
Intervention: rhTNK-tPA Thrombolysis
Description: rhTNK-tPA Thrombolysis
Study NCT04997876 — intervention group
Intervention type: OTHER
Intervention: Biomarker analysis
Description: Biomarkers from presurgical OCTs are assessed
Study NCT04424225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
Study NCT04424225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: 100 mg capsules (white opaque, Capsugel Vcaps Plus HPMC size 2)
Study NCT04687852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
Study NCT04687852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
Study NCT04687852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative and Non-conservative treatments
Description: This program includes Focused Pelvic Floor with Motor Imagery Technique Group ,Nonsteroidal Anti-Inflammatory Drug Group, Diosmin Group, Acupressure Group (LI-4 (Bilateral), CV-6, CV-4, SP-6 (Bilateral). It is aimed to determine the most effective treatment among these groups.
Study NCT04865588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rotational atherectomy
Description: angioplasty with rotational atherectomy - a rotating instrument used to break up the calcification
Study NCT04865588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting balloon
Description: a balloon with microsurgical blades on its outer surface which make longitudinal incisions in the calcified area in order to open resistant clogs
Study NCT04865588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plain old balloon
Description: current standard treatment of stent placement
Study NCT05277168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904
Description: Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
Study NCT05286853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Participants receiving institutional standard of care will have a kidney biopsy followed by 2 REACT injections into biopsied and non-biopsied contralateral kidneys 3 months (+30 days) apart and will be followed for 5 years (60 months) since last REACT injection.
Study NCT05286853 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Participants receiving institutional standard of care will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 3 months (+30 days) after the first sham procedure. Participants will be followed for 5 years (60 months) since last sham REACT injection.
Study NCT05388981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SBT115301
Description: Immunomodulatory dimeric fusion protein
Study NCT05388981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT04993105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + Graston.
Description: In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~.
Study NCT04993105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise only
Description: gastrocnemius and plantarstretching
Study NCT06316895 — intervention group
Intervention type: PROCEDURE
Intervention: thyroid surgery
Description: thyroid lobectomy
Study NCT06316895 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound-guided thermal ablation
Description: radiofrequency ablation; microwave ablation or laser ablation
Study NCT04633681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweetener and sweetness enhancer consumption
Description: Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
Study NCT05908396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-2644
Description: IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
Study NCT05689203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128
Description: dose 1
Study NCT05689203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128
Description: dose 2
Study NCT05689203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04981795 — intervention group
Intervention type: DRUG
Intervention: Tafasitamab
Description: Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
Study NCT06273449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 3 - 3D Printed Removable Partial Denture
Description: Teeth Profile Capture Method: Intraoral scan RPD Design Method: Based on intraoral scan, using design software RPD Fabrication Method: Additive manufacturing
Study NCT06273449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 2 - 3D Printed Removable Partial Denture
Description: Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using design software RPD Fabrication Method: Additive manufacturing
Study NCT05162274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib(G001)
Description: Current formulation
Study NCT05162274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib(G002)
Description: New formulation
Study NCT05451004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic Mapping with SPECT-CT
Description: Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
Study NCT05451004 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ipsilateral and Contralateral Neck
Description: Radiotherapy
Study NCT04635969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health and Development Education for Children With Intellectual Disability
Description: Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
Study NCT05181787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Study NCT05181787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Metabolomic data were obtained by UPLC-QTOF/MS platform.
Study NCT05217667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-ANG 3 Injection
Description: Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
Study NCT06031103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mini-PCNL procedure
Description: Mini-PCNL~. A 12 Fr rigid nephroscope and a Holmium:YAG laser as energy source was used for surgery Percutaneous renal puncture was achieved with an 18 Ga needle after displaying renal collecting system with contrast material. and tract dilatation was achieved using Amplatz dilators up to 16-18 Fr according to patient age
Study NCT06031103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS procedure
Description: RIRS Technique the 9.5 Fr ureteral access sheath (UAS). UAS was inserted over the guide wire under fluoroscopy control. A flexible ureteroscope was passed through the UAS. If the UAS did not pass over the guide wire, the investigator moved the flexible ureteroscopy over the guide wire without access sheat
Study NCT04912687 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EGFR gene mutation analysis on liquid biopsy
Description: Blood samples will be collected at inclusion for plasma DNA collection and analysis.
Study NCT04907019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin，SY-004
Description: On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22.
Study NCT04472416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRD in addition to standardized analgesic protocol
Description: Use of VRD in addition to standardized analgesic protoco for abdominal VAC dressing change
Study NCT05185505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
Study NCT05185505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
Study NCT04468594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rigid tapping
Description: Taping techniques We will use rigid tape and apply it bilaterally. In the rigid tape application, a combination pack of zinc oxide tape and the protective tape will be used. The protective tape will be applied first with no tension. To apply the rigid tape, subjects will be instructed to place their thoracic spine in a neutral position, the rigid tape will be applied bilaterally from the first to the twelfth thoracic vertebra. Subjects will be asked to retract and depress the scapula. The rigid tape will be applied diagonally from the middle of the scapular spine to the twelfth thoracic vertebra; this technique will be applied bilaterally. The rigid tape will be applied 3 times per week and will be applied for 6 weeks.
Study NCT04468594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular stabilizing excercise
Description: consisted of:~1. wall slides with squat,~2. wall push-ups plus ipsilateral leg extension,~3. lawnmower with diagonal squat,~4. resisted scapular retraction with contralateral leg squat and robbery with squat.~5. Robbery with squat~6. Resisted shoulder internal rotation with step~7. Resisted shoulder external rotation with step~8. Resisted full can with step All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands The patient will perform 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly.
Study NCT04468594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: 1. Pectoralis minor stretching~2. Posterior shoulder stretching~3. Levator scapula stretching~4. Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~5. Resisted shoulder internal rotation~6. Resisted shoulder external rotation~7. Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets.
Study NCT04468594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: 1. Pectoralis minor stretching~2. Posterior shoulder stretching~3. Levator scapula stretching~4. Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~5. Resisted shoulder internal rotation~6. Resisted shoulder external rotation~7. Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets.
Study NCT05695560 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study NCT06122675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS
Description: Implanted in the cerebellum.
Study NCT06122675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS
Description: Implanted in the cerebellum.
Study NCT05092126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Calculate oxygen consumption
Study NCT06405100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care+Prednisone
Description: Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Induction period: 1mg/kg/day. The maximum dose is not more than 60mg. The duration of adequate prednisone is a minimum of 4 weeks and a maximum of 16 weeks.~Maintenance period: A reduction of 5-10mg/wk was initiated after 2 weeks of complete remission and finally discontinued after 6 months of maintenance at 5mg/day.
Study NCT06405100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care+Tacrolimus+Ripertamab
Description: Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Tacrolimus：Induction period: 0.05mg/kg/d. It will be given in two doses 12 hours apart. The blood concentration should be up to 5-10ng/ml. Maintenance therapy was initiated two weeks after complete remission; Maintenance period: Reduced to a blood concentration of 3-8ng/ml, and stopped after 6 months of maintenance treatment.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months.
Study NCT05798715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleptomet 50/1000(Metformin HCl & Sitagliptin)
Description: Test drug
Study NCT05798715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Janumet 50/1000(Metformin HCl & Sitagliptin)
Description: Reference drug
Study NCT06331663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: first start with remifentanil 5.0 ng/ml, and use the up and down method as adjust 0.5 ng/ml of concentration of remifentanil each time. Inadequate antinociception (Surgical Pleth Index(SPI) > 80 and hyperdynamics (the increased heart rate (HR) and mean blood pressure (MBP) above 20% of baseline or HR>100bpm and arterial blood pressure(ABP)>180/100mmHg)) is defined as failure, therefore we increase remifentanil by 0.5 ng/ml; otherwise, the setting is considered successful without abovementioned situations.
Study NCT06225843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotevtamab
Description: Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
Study NCT06225843 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
Study NCT06405100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care+Ripertamab
Description: Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months.
Study NCT05049057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab 140 Mg/mL Subcutaneous Solution
Description: Active erenumab delivered via subcutaneous injection.
Study NCT05049057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered via subcutaneous injection.